Share

Press Releases

Press release year list 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006
October 7, 2020
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a fourth quarter 2020 dividend payable to holders of the company’s common stock of $0.20 per share. The dividend is to be paid on Tuesday, Dec. 1, 2020, to holders of record on Wednesday, Oct. 21, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This ...
September 30, 2020
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 5, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2020 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Nov. 5, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis ...
September 15, 2020
Zoetis recognized by Working Mother magazine for its career advancement opportunities, female representation and work-life programs Manufacturing Site Leader Renee Peng named Zoetis’ 2020 Working Mother of the Year Zoetis Inc . (NYSE: ZTS) today announced that it has been named one of Working Mother magazine’s "100 Best Companies for Working Mothers" for the seventh consecutive year. The publication selects the top 100 companies in the U.S. that lead in areas of female representation and advancement, benefits, parental leave, childcare and flexible work arrangements. “The COVID-19 pandemic has presented unprecedented challenges to all of our colleagues, but especially our working parents this year. They have been called on like never before to juggle childcare, remote schooling, family needs and work demands all amidst uncertain, stressful and changing times,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations at Zoetis. “Now more than ...
September 10, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the 18th Annual Morgan Stanley Healthcare Conference on Wednesday, Sept. 16, 2020. Kristin Peck, Chief Executive Officer, and Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. They are scheduled to present virtually at 8:00 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock ...
September 9, 2020
Diagnostic tool provides veterinarians the ability to identify parasites,
view images and share results with pet owners within nine minutes Today Zoetis announced the launch of Vetscan Imagyst™, a diagnostic platform that uses a combination of image recognition technology, algorithms and cloud-based artificial intelligence (AI) to deliver accurate testing results to the clinic.  Imagyst’s first indication will be for testing fecal samples for parasites, and it has the potential for broader applications to different types of testing in the future.  Imagyst was developed to first help veterinarians make accurate and timely point-of-care intestinal parasitic diagnoses for dogs and cats. With deep learning capability powered by artificial intelligence, Imagyst revolutionizes in-clinic fecal testing during the time of visit by giving veterinarians the ability to accurately diagnose patients quickly and treat if necessary. Intestinal parasites remain a prevalent issue in ...
August 6, 2020
Reports Flat Revenue of $1.5 Billion, and Net Income of $377 Million, or $0.79 per Diluted Share, Increasing 2% and 3%, Respectively, on a Reported Basis for Second Quarter 2020 Reports Adjusted Net Income of $427 Million, or Adjusted Diluted EPS of $0.89 for Second Quarter 2020 Delivers 4% Operational Growth in Revenue and 4% Operational Growth in Adjusted Net Income for Second Quarter 2020 Raises and Narrows Full Year 2020 Revenue Guidance to $6.300 - $6.475 Billion and Diluted EPS of $3.14 - $3.32 on a Reported Basis, or $3.52 - $3.68 on an Adjusted Basis Zoetis Inc . (NYSE: ZTS) today reported its financial results for the second quarter of 2020 and raised and narrowed its guidance for full year 2020 to reflect the company’s current view of the estimated full-year impact of the COVID-19 pandemic and foreign currency headwinds. The company reported revenue of $1.5 billion for the second quarter of 2020, which is flat compared with the second quarter of 2019. Net income for the ...
July 21, 2020
ZoetisOpens in a new window  has acquired  Virtual RecallOpens in a new window , an innovative business that helps veterinary practices to improve their service offering and communication with pet owners. “This is an exciting opportunity for Zoetis to add a new solution for veterinarians with an innovative service that will support clinics in increasing their level of compliance, education and engagement at the pet owner level,” said Jamie Brannan, Senior Vice President UK, Ireland and Nordics. “As we expand our comprehensive offering across the continuum of care for veterinary clinics, Virtual Recall will enhance the level of pet owner services that can be offered to their pet owner customers in the UK, Australia and New Zealand,” he added. “Our studies have shown that veterinary customers are keen to reduce administrative workload and find new ways to engage with pet owners. We believe that Virtual Recall will achieve that, helping to educate and improve pet owner ...
July 7, 2020
Trianni, Inc. (TRIANNI) and Zoetis (NYSE: ZTS) today announced a collaboration for the development of transgenic monoclonal antibody platforms for the discovery of new veterinary treatments. “We are confident that the application of TRIANNI’s proven transgenic human monoclonal antibody discovery platform technology to the veterinary field will add value to Zoetis' product development programs," said Matthias Wabl, Ph.D., Trianni’s President and CEO. "We appreciate TRIANNI's experience in the development of therapeutic antibody platform capabilities and look forward to working with them on innovations for animal health," said Catherine A. Knupp, D.V.M., M.S., Executive Vice President and President, Research and Development at Zoetis. "This collaboration will enhance our internally-developed pipeline of novel monoclonal antibodies and hasten the develop­ment of therapeutics that could transform the way veterinarians treat a range of diseases in animals." No financial details were ...
July 1, 2020
Additional Labs and Environmental Testing Further Complement Pharmaq’s Offering to Fish Producers in Key Aquaculture Markets Zoetis today announced the acquisition of Fish Vet Group from Benchmark Holdings, PLC, as a strategic addition to its Pharmaq business which develops and commercializes fish vaccines and offers services in vaccination and diagnostics for aquaculture. Adding Fish Vet Group grows the geographic reach and enhances the diagnostics expertise and testing services, including environmental testing, that Pharmaq’s reference lab Pharmaq Analytiq now can offer fish farmers in major aquaculture markets. Fish Vet Group is headquartered in Inverness, Scotland, with diagnostic lab locations there as well as in Norway, Ireland and Chile, where it provides veterinary services and services in bacteriology, histology and PCR testing. To help fish producers comply with strict environmental standards, Fish Vet Group offers surveys and analysis to monitor potential environmental ...
June 26, 2020
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Aug. 6, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review second quarter 2020 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Aug. 6, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. ...
June 16, 2020
After three years of co-funding with the Bill & Melinda Gates Foundation, nearly 400,000 farmers trained in animal care, more than 60 animal medicines approved for use and new diagnostic and vaccine care initiatives in place.  ZAVENTEM, BELGIUM – June 16, 2020 – In its third year,  Zoetis ’ African Livestock Productivity and Health Advancement (A.L.P.H.A.) initiative, co-funded with a $14 million grant from the Bill & Melinda Gates Foundation, continues to improve livestock health and positively impact farmers’ livelihoods by increasing access to quality veterinary medicines and services, diagnostic laboratory networks, and animal health training in sub-Saharan Africa. “Animal health is extremely important in contributing to sustainable development goals and economic opportunities in Africa,” said Rob Kelly, President International Operations at Zoetis. “Access to medicines and technology will help farmers raise healthier animals and secure a more productive and ...
June 8, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the William Blair 40th Annual Growth Stock Conference on Thursday, June 11, 2020. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 12:20 p.m. ET (11:20 a.m. CT). Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, ...
May 20, 2020
Zoetis Inc . (NYSE:ZTS) today announced the results of shareholder voting at its 2020 Annual Meeting of Shareholders and provided details on its third quarter 2020 dividend. Virtual Annual Meeting of Shareholders Zoetis held a virtual annual meeting today, with Chairman Michael B. McCallister presiding over the business portion of the meeting and shareholder voting. Chief Executive Officer Kristin Peck discussed the company’s strong performance in 2019, the essential role that Zoetis plays in sustaining and protecting animal and human life during the COVID-19 pandemic, and its top priorities for continued growth and market leadership in the global animal health industry. As part of her remarks about the company, Peck said, “In 2019, we achieved operational revenue growth of 10% and grew adjusted net income 14% operationally, while continuing to create value for our investors.” “As we started 2020, none of us could have predicted the circumstances we would face as a company and a ...
May 18, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the Stifel 2020 Virtual Jaws & Paws Conference on Wednesday, May 27, 2020. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 12:40 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations . A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for ...
May 7, 2020
Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 2.000% senior notes due 2030 and $500 million aggregate principal amount of 3.000% senior notes due 2050, in an underwritten public offering. Zoetis intends to use the net proceeds to repay the principal of our 3.450% senior notes due 2020 in the aggregate principal amount of $500 million and for general corporate purposes. The offering is expected to close on May 12, 2020, subject to customary closing conditions. Barclays Capital Inc., BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC and MUFG Securities Americas Inc. are acting as joint book-running managers of the underwriters. The final prospectus supplement and accompanying prospectus, when available, may be accessed through the SEC’s website at www.sec.gov . Alternatively, the issuer, the underwriters or any dealer participating in the offering ...
May 6, 2020
Reports Revenue of $1.5 Billion, Growing 5%, and Net Income of $423 Million, or $0.88 per Diluted Share, Increasing 36% and 35%, Respectively, on a Reported Basis for First Quarter 2020 Reports Adjusted Net Income of $455 Million, or Adjusted Diluted EPS of $0.95, for First Quarter 2020 Delivers 7% Operational Growth in Revenue and 10% Operational Growth in Adjusted Net Income for First Quarter 2020 COVID-19 Pandemic Has Minimal Impact on First Quarter Results; Estimated Full-Year Impact Reflected in Lower 2020 Guidance Updates Full Year 2020 Revenue Guidance to $5.950 - $6.250 Billion and Diluted EPS of $2.80 - $3.07 on a Reported Basis, or $3.17 - $3.42 on an Adjusted Basis Zoetis Inc. (NYSE: ZTS) today reported its financial results for the first quarter of 2020 and lowered its guidance for full year 2020 to reflect the company’s current view of the estimated full-year impact of the COVID-19 outbreak, recessionary conditions in the global economy, and foreign currency headwinds. ...
April 30, 2020
Launched by leading animal health company Zoetis Uniquely combines preventive care with best-in-class health insurance for dogs and cats Pumpkin Insurance Services , Inc. (“Pumpkin”), a new pet insurance agency and pet care company, announced today the launch of its new insurance and optional monthly preventive care plans for pet owners in the U.S. Launched by Zoetis (NYSE:ZTS), the world’s largest global animal health company, Pumpkin is now available to consumers in many states. 1 With its holistically designed plans, Pumpkin addresses a gap in the pet care industry by offering competitive pet health insurance and preventive care so pet owners can help their pets stay healthy year-round. Rather than wait until animals are sick or injured to provide care, Pumpkin’s Preventive Essentials plan – available at an additional cost to the core insurance plan – helps enable families to give their pets crucial routine care that veterinarians universally recommend for cats and dogs. ...
April 17, 2020
Zoetis Inc. (NYSE: ZTS) has been notified of an unsolicited “mini-tender offer” by TRC Capital Investment Corporation (“TRC”) to purchase up to 1,000,000 shares of Zoetis common stock, representing approximately 0.21% of the outstanding shares of Zoetis common stock. TRC’s offer price of $109.00 per share is approximately 4.9% lower than the $114.61 closing price per share of Zoetis common stock on April 3, 2020, the last trading day before the commencement of the offer, and approximately 14.5% below the $127.45 closing price per share of Zoetis common stock on April 16, 2020, the last trading day before the date of this press release. TRC has made similar, unsolicited mini-tender offers for shares of other publicly traded companies. Zoetis does not endorse TRC’s unsolicited mini-tender offer and is not associated in any way with TRC, its mini-tender offer or its mini-tender offer documents. TRC’s offer price is below the current market value for shares of Zoetis common stock. In ...
April 8, 2020
Zoetis today announced the acquisition of Performance Livestock Analytics to enhance its animal health solutions across the continuum of care for beef producers. The addition of Performance Livestock Analytics, a technology company that simplifies data and analytics for the livestock industry, will help Zoetis to accelerate progress in precision livestock farming and improve sustainability of producers’ operations. Financial terms of the transaction are not being disclosed. Performance Livestock Analytics was the first company to offer cloud-based data management to beef producers. Today, its innovative Performance Beef solution combines cloud-based technology with automated on-farm data collection to provide powerful analytics that help feedlot managers make better decisions across financials, nutrition and animal health. Simplifying feeding to financials, Performance Beef makes it easy to change rations; create accurate invoices and closeout reports; and analyze trends in feed ...
April 1, 2020
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Wednesday, May 6, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review first quarter 2020 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations . Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on May 6, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis ...
March 3, 2020
Zoetis Inc. (NYSE: ZTS) today announced that it has been named one of the 2020 “Top 70 Companies for Executive Women” by the National Association for Female Executives. This honor recognizes U.S. corporations where there is a strong focus on best practices that demonstrate effectiveness in moving women to senior ranks, including mentoring, involvement in employee-resource groups and leadership development training. “We are honored to once again be recognized by NAFE for our advancement and development programs for women,” said Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Global Operations at Zoetis. “Under the leadership of our new CEO Kristin Peck , we encourage and support every colleague as they grow personally and professionally and pursue their career goals and aspirations. We view our people as our biggest strength, and we are committed to offering development opportunities that engage and empower all of our colleagues.” NAFE ranked Zoetis most ...
February 27, 2020
Simparica Trio marks the first all-in-one protection in the U.S. against heartworm disease, ticks* and fleas, roundworms and hookworms** in a single monthly chewable First parasiticide to combine sarolaner, moxidectin and pyrantel First combination isoxazoline for dogs in the U.S. New product protects against many of the most common parasites and gives veterinarians and pet owners a convenient option for comprehensive protection Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved Simparica Trio TM (sarolaner, moxidectin, and pyrantel chewable tablets), the first once-monthly, chewable tablet in the U.S. that delivers all-in-one protection from heartworm disease, ticks and fleas, roundworms and hookworms. This combination product builds on the trusted legacy of Simparica ® (sarolaner) Chewables and exemplifies Zoetis’ dedication to innovation in parasiticides. “Today’s approval of Simparica Trio in the United States provides veterinarians with a new and ...
February 21, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020, in Boston, Mass. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 2:10 p.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who ...
February 13, 2020
For Fourth Quarter 2019, Zoetis Reports Revenue of $1.7 Billion, Growing 7%, and Net Income of $384 Million, or $0.80 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $440 Million, or Adjusted Diluted EPS of $0.92, for Fourth Quarter 2019 Delivers 9% Operational Growth in Revenue and 13% Operational Growth in Adjusted Net Income for Fourth Quarter 2019 For Full Year 2019, Zoetis Reports Revenue of $6.3 Billion, Growing 7%, and Net Income of $1.5 Billion, or $3.11 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $1.8 Billion, or Adjusted Diluted EPS of $3.64, for Full Year 2019 Delivers 10% Operational Growth in Revenue and 14% Operational Growth in Adjusted Net Income for Full Year 2019 Provides Full Year 2020 Revenue Guidance of $6.650 - $6.800 Billion, with Diluted EPS of $3.53 - $3.65 on a Reported Basis, or $3.90 - $4.00 on an Adjusted Basis Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year ...
February 11, 2020
The Board of Directors of Zoetis Inc . (NYSE:ZTS) has declared a second quarter 2020 dividend payable to holders of the company’s common stock of $0.20 per share. The dividend is to be paid on Monday, June 1, 2020, to holders of record on Friday, April 17, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2018, the company generated annual revenue of $5.8 billion with approximately 10,000 employees. For more information, visit www.zoetis.com . DISCLOSURE NOTICES Forward-Looking Statements: This press ...
February 10, 2020
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Animal Health Summit on Monday, Feb. 24, 2020, in New York, N.Y. Glenn David, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 8:40 a.m. ET. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Zoetis serves veterinarians, livestock ...
February 7, 2020
Zoetis Inc . (NYSE:ZTS) today announced the acquisition of Ethos Diagnostic Science, a veterinary reference lab business dedicated to serving leading specialty animal hospitals, the greater veterinary community and researchers with accurate, reliable results. Having entered the veterinary reference laboratory space through the acquisitions of both Phoenix Lab and ZNLabs in 2019, Zoetis continues to grow its diagnostics presence to offer comprehensive and enhanced value to veterinarians in the U.S. Financial terms of the transaction are not being disclosed. Ethos Diagnostic Science is a business unit of Ethos Veterinary Health and has laboratory locations in Boston, Denver and San Diego. Its clinical team has decades of combined experience in veterinary and laboratory medicine and is proud of the strong client relationships built through comprehensive review of accurate, reliable results for the best possible patient outcomes. Ethos Diagnostic Science performs testing for all ...
January 2, 2020
Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Feb. 13, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review fourth quarter and full year 2019 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be made available on Feb. 13, 2020. About Zoetis Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of ...